tissue binding contributes to the initial uptake and storage of drug in the liver, except in unusual situations, this is a reversible process, and such binding does not affect the irreversible removal of drug by the clearance processes. Accordingly, such a mechanism does not need to be invoked to explain the increased first-pass effect of drugs, including lidocaine, produced by the administration of enzyme-inducing agents.

(1) M. Rowland, L. Z. Benet, and G. G. Graham, *J. Pharmacokinet. Biopharm.*, **1**, 123 (1973).

(2) G. R. Wilkinson and D. G. Shand, *Clin. Pharmacol. Ther.*, **18**, 377 (1975).

(3) K. S. Pang and M. Rowland, *J. Pharmacokinet. Biopharm.*, **5**, 625 (1977).

(4) J. R. Gillette and K. S. Pang, *Clin. Pharmacol. Ther.*, **22**, 623 (1977).

(5) J. R. Gillette, *J. Pharm. Sci.*, **71**, 673 (1982).

(6) A. Rane, G. R. Wilkinson, and D. G. Shand, *J. Pharmacol. Exp. Ther.*, **200**, 420 (1977).

(7) W. A. Colburn, *J. Pharm. Sci.*, **70**, 969 (1981).

(8) E. Perucca and A. Richens, *Br. J. Clin. Pharmacol.*, **8**, 21 (1979).

(9) G. T. Tucker and L. E. Mather, *Br. J. Anaestheol.*, **47** (Suppl.), 213 (1975).

(10) N. Benowitz, R. P. Forsyth, K. L. Melmon, and M. Rowland, *Clin. Pharmacol. Ther.*, **16**, 87 (1974).

(11) M. Gibaldi and S. Feldman, *J. Pharm. Sci.*, **58**, 1477 (1969).

P. J. Wedlund
G. R. Wilkinson[x]
Department of Pharmacology
Vanderbilt University
Nashville, Tennessee 37232

Received January 4, 1983.
Accepted for publication June 16, 1983.
Supported in part by USPHS Grant GM 31304.

OPEN FORUM

Aspirin Prodrug Studies: Lack of Proper Literature Citation

I read with great interest the recent article by Hussain *et al.*, *J. Pharm. Sci.*, **72**, 1093 (1983), which contradicts the observations of Amidon *et al.*, *J. Pharm. Sci.*, **70**, 1299 (1981), concerning the question of aspirin phenylalanine ethyl ester as an aspirin prodrug.

Although the former article unequivocally demonstrates the inadequacies of the latter, it appears that both senior authors have been remiss in acknowledging the important contributions of other investigators in the development of aspirin prodrugs.

In particular, the aspirin triglyceride works of Paris *et al.*, *J. Med. Chem.*, **22**, 683 (1979) and *Agents and Actions*, **10**, 240 (1980) are never cited. More importantly, the only published article which describes the detection of aspirin in the plasma after *in vivo* administration of a prodrug of aspirin is conspicuously absent, Bodor *et al.*, *J. Pharm. Sci.*, **70**, 743 (1981).

The lack of proper literature citation by these authors is a poor reflection of the care taken by them in the preparation of their manuscripts, and is also a reflection on the quality of the reviewers who would allow such an obvious lack of citation to occur.

James J. Kaminski
Schering Corporation
Bloomfield, NJ 07003

Received December 22, 1983.